Vivos Therapeutics Closes Exercise of 1.98M Warrants, Raising $4.64M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Successful Financing: Vivos Therapeutics has successfully exercised 1,982,356 warrants, raising approximately $4.64 million, demonstrating the company's active presence in capital markets and enhancing its operational funding.
- New Warrants Issued: In exchange for cash exercise, the company issued 3,964,712 new warrants at an exercise price of $2.09 per share, which is expected to further improve the company's capital structure and financing flexibility.
- Market Positioning: Vivos focuses on treating obstructive sleep apnea (OSA) with its innovative devices cleared by the FDA, indicating significant market potential that is likely to attract more investor interest.
- Future Development Plans: The company intends to use the proceeds for working capital and general corporate purposes, reflecting its confidence in future growth and ability to seize market opportunities.
Analyst Views on VVOS
Wall Street analysts forecast VVOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VVOS is 5.00 USD with a low forecast of 2.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.070
Low
2.50
Averages
5.00
High
7.00
Current: 2.070
Low
2.50
Averages
5.00
High
7.00
About VVOS
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
